| abstract |
FIELD: chemistry. n SUBSTANCE: invention refers to compounds of formula (I) or its pharmaceutically acceptable salt where radicals R 1 , R 2 , n 1 and n 2 , Y and X are valued in the description, R 3 stands for heterocyclic group of corollary formula (bb) (specified below). These compounds are phosphodiesterase (PDE) inhibitors, particularly PDE4 inhibitors. There is also disclosed production process of pharmaceutical compositions containing compound of formula or its pharmaceutically acceptable salt as an active component, and their application in manufacturing of a medicine for treatment and/or prevention of inflammatory and/or allergic disease in mammals, including humans, e.g. asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, allergic rhinitis, rheumatoid arthritis, disseminated sclerosis, Alzheimer's disease, depression or pain in mammals, including humans. n EFFECT: higher effectiveness of the composition and medication therapy. n 20 cl, 686 ex |